NASDAQ OMX

VistaJet Records 39% EBITDA Growth With Strong First Quarter 2017 Results

Dela

VistaJet continues to gain market share across all markets

For the 13 weeks to 31 March 2017:

  • Flight revenues increased by 22% globally year-over-year.
  • EBITDA grew 39% year-over-year due to increased yields and efficiency.
  • New Program hours sold up 79% Q1 2017 against Q1 2016.
  • Program Membership accounts for majority of total hours flown in Q1 2017 at 55%.

LONDON, June 01, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, has today announced yet another record quarter, again demonstrating its ability to consistently capture greater market share with its strong value proposition of asset free risk and truly global access.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/9e3d1364-eb1f-4e73-aa64-4dbcecb3cf76

The company recorded EBITDA growth of 39% year-on-year following a record Q1 sales success, and increased yields and efficiency due to its global infrastructure and a continued focus on technology.

The company's decision to grow its fleet to a total of over 70 identically branded and globally positioned aircraft continues to support its growth, and the average utilization trend was positive month-on-month from January 2017 to March 2017.

In the traditionally weakest quarter of the year for the aviation industry, VistaJet recorded a 22% growth in flight revenues year-on-year. The majority of growth came from VistaJet's Program segment, with existing customers utilizing and upsizing their contracts and new clients choosing to subscribe to multi-year agreements. Sales of new annual Program hours increased by 79% year-on-year, demonstrating the company's position as the only alternative to full or fractional aircraft ownership in the private aviation market. Program customers flew more hours in the first quarter than in any other period in VistaJet's history, accounting for 55% of total hours globally, up from 53% against the same quarter last year.

VistaJet's On Demand segment also grew year-on-year, with revenues increasing by 14% in spite of Easter falling outside of Q1 this year. Total On Demand flight hours remained steady year-on-year whilst live hours increased by a staggering 4% as the improvement in the ferry factor drove a decline in empty flight hours. Empty legs have long been a challenge for private aviation businesses, as companies with less scale and operational efficiency have to relocate their aircraft to pick up passengers. The company recently announced a 'Ferry Free World' for its Program clients.

VistaJet continues to record growth across the globe. The company increased its market share not only in the U.S. and Asia, both key target growth markets, but also in the more mature markets of Europe, Russia and CIS. VistaJet saw an increase of 15% year-on-year in flight hours in Europe, highlighting that the company continues to see significant growth potential in its established markets.

The U.S. business remains a driving factor in VistaJet's flight hour growth and prospect pipeline. Flight hours in North America increased by 54% year-on-year. The company also increased its regional customer base and the number of aircraft positioned in the area, which helped it to deliver flight hours growth of 43% also in Central and South America.

VistaJet performed strongly in Asia, and Program customers within the region accounted for 25% of total hours sold during Q1 2017. As a result of their global flying and access needs, both corporate and private individual Program customers in Asia are mainly flying outside of the region to Europe, the Middle East and North America, helping to drive an increase in global flight hours.

VistaJet will continue to grow hours and revenues on its established and leading aircraft and technology infrastructure, improving utilization, margins and the company's financial strength. VistaJet, as the leading global private aviation company, is continuing to benefit from the trends away from asset ownership and secure new customers who previously had to choose between whole aircraft, fractional ownership, and an inconsistent and inferior charter offering.

About VistaJet

VistaJet is the first and only global aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries worldwide. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers pay only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program service offers customers a bespoke subscription of flight hours on its fleet of mid and long range jets, to fly them anywhere and at any time.

More VistaJet information and news at vistajet.com.

Information

Jennifer Tyler
VistaJet International
T: +44 203 617 3077
M: +44 7834 335505
jennifer.tyler@vistajet.com 

James Leviton
Finsbury
+44 207 251 3851
VistaJet@finsbury.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference21.11.2017 15:15Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace. A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and comme

OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics21.11.2017 14:00Pressmeddelande

Acquisition Will Expand OmniComm's Product Line With Data Analytics and Risk-Based Monitoring Solutions FORT LAUDERDALE, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, and  Algorithm, Inc. and its subsidiaries Algorics Ltd. and Algorithm Informatics Pvt. Ltd. (collectively, "Algorics"), have signed a letter of intent ("LOI"), under which OmniComm will acquire certain assets and assume certain liabilities of Algorics, a provider of clinical analytics solutions and software. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry. The transaction would also provide OmniComm with an office in India, a country of growing importance in t

CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs21.11.2017 14:00Pressmeddelande

SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies. The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers: Peterson et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856  Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model PLOS One 2017;1

Port Moresby Stock Exchange (POMSoX) Launches New Nasdaq Trading System21.11.2017 11:31Pressmeddelande

NEW YORK and PORT MORESBY, Papua New Guinea, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Nasdaq Inc. (NASDAQ:NDAQ) and the Port Moresby Stock Exchange (POMSoX) have announced that POMSoX has gone live with the widely deployed Nasdaq Matching Engine that operates on the Nasdaq Financial Framework platform. The launch of the new trading platform is a result of an upgrade from previous Nasdaq trading technology. The new trading engine will handle the trading of equities in the Papua New Guinea market. POMSoX has been a customer of Nasdaq since 1999.  "The Nasdaq trading platform will allow significant innovation in terms of market design and market offerings," said Johnson Kalo, a POMSoX board member said. "We believe the platform will provide strong support for future growth in the PNG market and provide new business opportunities in areas such as market data distribution." "We are pleased to continue to support POMSoX, a longstanding Nasdaq customer," said Robert Frojd, Regional Man

CloudCraze Joins the Pledge 1% Movement, Makes Commitment to Philanthropic Leadership21.11.2017 08:00Pressmeddelande

CloudCraze will leverage profit and employee time to improve communities around the world LONDON, Nov. 21, 2017 (GLOBE NEWSWIRE) -- CloudCraze, the enterprise B2B commerce platform built natively on Salesforce, has joined Pledge 1%, a corporate philanthropy movement dedicated to making the community a key stakeholder in every business. Spearheaded by Atlassian, Rally, Salesforce and Tides, Pledge 1% empowers companies to donate 1% of product, 1% of equity, 1% of profit or 1% of employee time to improve communities around the world. CloudCraze is joining an impressive network of entrepreneurs and companies across the globe that have committed to philanthropic efforts through the Pledge 1% movement. By pledging 1% of its profit and employee time, CloudCraze is demonstrating a commitment to philanthropic leadership. "We are incredibly excited that CloudCraze has taken the pledge," said Amy Lesnick, chief executive of Pledge 1%. "CloudCraze can play a pivotal role i

HemChecks avläsare kalibrerad med toppresultat - Regulatorisk20.11.2017 16:18Pressmeddelande

HemChecks avläsare kalibrerad med toppresultat Det medicintekniska bolaget HemCheck, som utvecklar ett patientnära test för detektion av hemolys, kan idag meddela att den digitala avläsare som utgör en del av bolagets produktkoncept Helge, kalibrerats med mycket gott resultat. Detta skedde genom studier i egen regi. Avläsaren kan nu färdigställas och produktkonceptet kommer därmed ett steg närmare CE-märkning. Som ett led i att färdigställa bolagets produktkoncept Helge har HemCheck under hösten utfört studier i egen regi med hjälp av blod från frivilliga bloddonatorer. Syftet var att kalibrera avläsaren och på så sätt möjliggöra en patientnära avläsning av hemolys, det vill säga redan på ett tidigt stadium avgöra om blodprovet är användbart och kan ska skickas till analys.   -Enkelt utryckt har vi lärt avläsaren att mäta hemolys på våra engångstester. Det är en viktig milstolpe och en stor framgång. Nu känner vi oss redo

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum